The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04061018 |
Recruitment Status :
Active, not recruiting
First Posted : August 19, 2019
Last Update Posted : April 10, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Lipid Metabolism Disorders |
The mechanisms that underlie variation in cholesterol efflux are unknown. There is a critical need to identify factors that regulate cholesterol efflux to effectively advance the clinical development of cholesterol efflux as both a risk prediction marker and as a target of therapy. The investigator's long-term goal is to determine whether modulating cholesterol efflux prevents or reverses cardiovascular disease. The overall objective of this study is to systematically create a family pedigree and biobank repository of blood and DNA from participants from the Dallas Heart Study with extreme low or high cholesterol efflux, with the specific aims of : 1) determining the heritability of and genomic factors associated with cholesterol efflux, and 2) identifying the protein and lipid signature of extreme low and high cholesterol efflux in a sex- and ethnicity-specific manner. The investigator's central hypothesis is that a combination of genetic variation in lipid transporters as well as proteins and lipids will be most strongly correlated with variation in efflux.
DHS probands and their relatives (parents, siblings, adult children, grandparents, aunts/uncles, cousins) with extreme low or high cholesterol efflux will be recruited to establish a prospective family pedigree cohort and understand the heritability of extreme cholesterol efflux. Investigators will collect the following information from all participants: demographics, health history, lifestyle measures, and medications. Blood will be collected on-site by venipuncture and plasma, serum, and cells will be stored at -80o Celsius. All efflux measurements will be completed in the investigator's laboratory.
Study Type : | Observational |
Estimated Enrollment : | 180 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux |
Actual Study Start Date : | December 1, 2017 |
Actual Primary Completion Date : | December 1, 2023 |
Estimated Study Completion Date : | May 6, 2025 |
Group/Cohort |
---|
High Cholesterol Efflux
Dallas Heart Study participants who are above the sex and ethnicity specific 90th % of cholesterol efflux
|
Low Cholesterol Efflux
Dallas Heart Study participants who are below the sex and ethnicity specific 10th % of cholesterol efflux
|
- Contribution of genetic factors to variability in cholesterol efflux [ Time Frame: Anticipated completion date - November 2022 ]The expected outcome is establishing the degree of heritability of the extreme low or high cholesterol efflux phenotype, specific for sex and ethnicity and the contribution of common and rare genetic variants to cholesterol efflux. This will establish for the first time to what degree inherited verses environmental factors associate with variation in cholesterol efflux.
- Circulating metabolites and proteins linked to variation cholesterol efflux [ Time Frame: Anticipated completion date - November 2022 ]The investigators will measure circulating metabolites and proteins and identify the most relevant to the high/low cholesterol efflux phenotype, offering the potential to focus future studies targeting metabolic regulators of efflux.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 89 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Participants from the Dallas Heart Study (DHS) with extreme low or high cholesterol efflux will be recruited in this study. DHS is a multi-ethnic, population based probability sample of Dallas County designed to define the social and the biological variables contributing to ethnic differences in cardiovascular health at the community level.
https://www.utsouthwestern.edu/edumedia/edufiles/research/center_translational_medicine/dallas_heart_study/dhs-study-overview.pdf
Inclusion Criteria:
- Dallas Heart Study (DHS) Participants who are above or below the sex- and ethnicity-specific 10th and 90th% of cholesterol efflux.
- Family members of the DHS participants are also eligible
Exclusion Criteria:
- HIV
- Cancer
- Autoimmune diseases
- Pregnancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04061018
United States, Texas | |
UT Southwestern Medical Center | |
Dallas, Texas, United States, 75390 |
Principal Investigator: | Anand Rohatgi, MD | UT Southwetsern Medical Center |
Responsible Party: | Anand Rohatgi, Professor of Medicine, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT04061018 |
Other Study ID Numbers: |
STU 042016-020 1R01HL136724-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | August 19, 2019 Key Record Dates |
Last Update Posted: | April 10, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
HDL Atherosclerotic Cardiovascular Disease Cholesterol efflux |
Metabolic Diseases Lipid Metabolism Disorders |